NORTH AMERICA, EUROPE, AND AUSTRALIA PEANUT ALLERGY TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

Peanut allergy is an allergic response by individual on exposure to peanuts. The most severe allergic reaction to peanuts is anaphylaxis a life-threatening whole-body response to an allergen. Anaphylaxis should be treated immediately with epinephrine (adrenaline), typically administered in an auto-injector. Diagnosing a peanut allergy can be complicated. Symptoms can vary from person to person, and a single individual may not always experience the same symptoms during every reaction.

Market Dynamics

Key players operating in the North America, Europe, and Australia peanut allergy treatment market are focusing on adoption of growth strategies such as product approval for the treatment of peanut allergy which are expected to drive market growth during the forecast period. For instance, In September 2021, COUR Pharmaceuticals, a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) accepted the company's Investigational New Drug (IND) application for evaluation of COUR's CNP-201 in a proof-of-concept (Phase 1 / 2) study in people who are allergic to peanuts. Moreover, increasing adoption of inorganic growth strategies by market players and government organizations is expected to drive the market growth over the forecast period. For instance, in December 2021, the National Health Service, U.K., announced that the department of health signed an agreement with Aimmune Therapeutics, Inc., a Nestlé Health Science company to provide Palforzia in the U.K. The U.K. will be the first country to receive Palforzia in Europe.

Key features of the study

• This report provides in-depth analysis of the North America, Europe, and Australia peanut allergy treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
• It profiles key players in the North America, Europe, and Australia peanut allergy treatment market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, and Strategies
• Key companies covered as a part of this study include, DBV Technologies DBV Technologies, Aimmune Therapeutics, Inc., Prota Therapeutics Pty Ltd., COUR Pharmaceuticals, BlueWillow Biologics, HAL Allergy B.V., Allergy Therapeutics PLC., Novartis AG, Regeneron Pharmaceuticals, Inc., Vedanta Biosciences, Inc., Cambridge Allergy Ltd. (Camallergy), Angany Inc., Moonlight Therapeutics Inc., Allero Therapeutics B.V., Sanofi, Johnson & Johnson, Viatris Inc. (Mylan N.V.), Sun Pharmaceutical Industries Ltd., Bayer AG, Aurobindo Pharma Limited., Astellas Pharma Inc., Siolta Therapeutics, DESENTUM OY, ALK, Immunomic Therapeutics, Inc., and Stallergenes Greer Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The North America, Europe, and Australia peanut allergy treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the North America, Europe, and Australia peanut allergy treatment market.

Market Segmentation

• By Drug Type
  • Epinephrine
  • Antihistamine
    • Loratadine
    • Diphenhydramine
    • Others
  • Palforzia
  • Pipeline Drugs
    • Viaskin Peanut
    • Ligelizumab
    • CA002
    • PRT120
    • Dupilumab
• By Route of Administration
  • Oral
  • Parenteral
  • Intranasal
  • Epicutaneous
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights
  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Australia
• Key Players Insights
  • DBV Technologies
  • Aimmune Therapeutics, Inc.
  • Prota Therapeutics Pty Ltd.
  • COUR Pharmaceuticals
  • BlueWillow Biologics
  • HAL Allergy B.V.
  • Allergy Therapeutics PLC.
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.
  • Vedanta Biosciences, Inc.
  • Cambridge Allergy Ltd. (Camallergy)
  • Angany Inc.
  • Moonlight Therapeutics Inc.
  • Allero Therapeutics B.V.
  • Sanofi
  • Johnson & Johnson
  • Viatris Inc. (Mylan N.V.)
  • Sun Pharmaceutical Industries Ltd.
  • Bayer AG
  • Aurobindo Pharma Limited.
  • Astellas Pharma Inc.
  • Siolta Therapeutics
  • DESENTUM OY
  • ALK
  • Immunomic Therapeutics, Inc.
  • Stallergenes Greer Ltd.